Editor's note

This ExpertREACT article was originally published on 31 December 2009. Events, pipeline statuses and market positions described reflect the state of knowledge at that date.

The year that changed the industry

2009 started with the surprise $68bn acquisition of Wyeth by Pfizer, announced on January 26th. Pfizer - which had previously made selected smaller vaccine investments including Powdermed, Coley and Cytos - suddenly owned one of the most successful vaccine franchises to date: Wyeth's Prevnar (PCV-7) and its successor PCV-13. Throughout 2009 the merged company progressed PCV-13 towards approval, with the US FDA indicating it would take more time to complete its review. PCV-13 gained European approval during the year. Pfizer was also expected to focus in 2010 on its Phase II MenB vaccine candidate (rLP2086), which alongside Novartis' more advanced programme, could define a new blockbuster vaccine category. Pfizer also advanced a new Staphylococcus aureus vaccine (SA3Ag) into Phase I - the first new clinical S.aureus vaccine candidate for some years.

In March 2009, VacZine Analytics turned its attention to avian influenza (H5N1), sensing significant activity around company and government pandemic preparedness. The US HHS had by then allocated approximately $7bn to pandemic preparedness activities, a legacy of the Bush administration. Then, unexpectedly, in April 2009 a novel triple reassortant H1N1 influenza A virus emerged from Mexico - the 'swine flu' that would become the first influenza pandemic since 1968 and the dominant story of the second half of the year.

Pfizer-Wyeth acquisition
$68bn
Announced 26 January 2009; gave Pfizer ownership of the Prevnar pneumococcal franchise and PCV-13 successor vaccine in development

Looking ahead to 2010

As 2009 drew to a close, VacZine Analytics assessed that beyond the H1N1 windfall, meningococcal B and nosocomial segment vaccines remained the genuine long-term commercial growth drivers. Both Novartis and the newly enlarged Pfizer were pursuing MenB candidates. Companies were also accelerating corporate expansion strategies to stay ahead of newcomers - particularly Japanese players making their first serious moves into the global vaccine market. The key predictions for 2010 centred on MenACWY launches (Menveo, Menhibrix) and the continued advancement of MenB programmes towards regulatory filing.